Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 08 MARCH 2019

New Court Proceedings - February 2019

Smart & Biggar
Explore more from Smart & Biggar

For complete details about these proceedings, click here.

CanadaLitigation, Mediation & Arbitration
Smart & Biggar
Smart & Biggar
Author LinkedIn connections

For complete details about these proceedings, click here.

PMNOC Actions

abiraterone acetate (ZYTIGA): Janssen and BTG v Sandoz

abiraterone acetate (ZYTIGA): Janssen and BTG v Pharmascience

fingolimod (GILENYA): Novartis v Natco

fampridine (FAMPYRA): Biogen and Acorda v Pharmascience

Other Actions

naproxen/esomeprazole magnesium (VIMOVO): Mylan v AstraZeneca

fingolimod (GILENYA): Novartis v Accord, Apotex, Marcan, Mylan, Pharmascience, Taro and Teva

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

BLG At The SCC – What’s Coming In The Supreme Court’s Fall 2026 Sitting Schedule

The Supreme Court of Canada held its second annual ceremony marking the opening of the judicial year at its temporary home in the West Memorial Building, with Chief Justice highlighting the Court's increased caseload and architectural features. What significant constitutional and legal challenges will the Court address in its fall 2026 session, including cases on firearm regulations, Crown immunity, and vicarious liability?
CanadaLitigation, Mediation & Arbitration
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Article

Ontario Court Bifurcates Class Action As Practical Approach To Onerous Discovery Demands

An Ontario court granted a motion to bifurcate liability and damages stages in a class action alleging $500 million in hidden fees, finding that extensive documentary production requests were disproportionate and not relevant to determining liability. The decision addresses proportionality concerns in class actions where defendants face onerous discovery demands spanning millions of transactions over a decade.
CanadaLitigation, Mediation & Arbitration
Bennett Jones LLP
Bennett Jones LLP
Article

The Supreme Court Of Canada Reviews Québec’s Bill 21

Québec's Bill 21, enacted in 2019, bans public sector workers from wearing religious symbols and is shielded from most Charter challenges by the notwithstanding clause. The Supreme Court of Canada is now reviewing this controversial law, with a ruling expected as early as November 2026 or later in 2027. Former Minister of Justice Arif Virani discusses the court's struggle to balance competing constitutional principles in this landmark case.
CanadaLitigation, Mediation & Arbitration
Torys
Torys
Article

The Coldcard Exploit: Why Victims May Have Two Routes To Recovery

A five-year-old firmware defect in Coldcard hardware wallets has enabled attackers to systematically drain an estimated $116 million in Bitcoin from over 5,200 victims since July 2026. This unprecedented exploit raises critical questions about manufacturer liability and creates two distinct legal pathways for recovery: blockchain tracing against the perpetrators and potential litigation against Canadian manufacturer Coinkite for product defects that undermined the fundamental security promise of devices mar
CanadaLitigation, Mediation & Arbitration
WeirFoulds LLP
WeirFoulds LLP
Article

Health Canada Updates Policies On Foreign Regulatory Actions, Summary Reporting, Compliance & Enforcement And Requests For New Data

Health Canada issued revised guidance on notifying Health Canada of foreign actions, effective October 1, 2026. The revised guidance clarifies the requirements to notify Health Canada of certain foreign regulatory actions specified in subsection C.01.050(2) of the Food and Drug Regulations in the specified foreign jurisdictions, which involve a serious risk of injury to human health and are relevant to the safety of the drug.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Health Canada Obtains Permanent Injunction To Prevent Illegal Sale Of Injectable Peptides By Canlab Research

Health Canada has secured a permanent injunction against Canlab Research, a Quebec-based online retailer, preventing the company from manufacturing, distributing, or selling unauthorized injectable peptides in Canada. This enforcement action follows years of regulatory warnings and provisional court orders aimed at stopping the illegal sale of peptide drugs promoted with unproven health claims for anti-aging, weight loss, and athletic performance.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar